Circus Aktie 131725919 / DE000A2YN355
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
24.10.2025 07:30:03
|
EQS-News: Circus SE Secures Core Technologies Through Six New Defense Patents
|
EQS-News: Circus SE
/ Key word(s): Patent
Circus SE Secures Core Technologies Through Six New Defense Patents
Munich, October 24, 2025 – Circus SE (XETRA: CA1 / WKN: A2YN35) today announced the filing of six groundbreaking patents in the fields of defense and autonomous AI robotics. The intellectual property covers core technologies of the company’s proprietary autonomous AI robot system CA-M, specifically engineered for operation in security-critical and military environments. The newly filed patents encompass multiple aspects of autonomous food preparation of the company's developed AI robot CA-M. With these filings, Circus positions itself as a pioneer in dual-use robotics, where culinary autonomy converges with defense-grade technologies. With these patents, Circus reinforces its transformation from an early AI robotics innovator into a strategic deep-tech company operating at the intersection of artificial intelligence, automation, and defense infrastructure. The goal is to secure a leading position in the emerging market for autonomous support systems across NATO and allied forces. In the defense domain, these patents establish significant competitive barriers for new entrants, allowing Circus to deploy protected technology while forcing competitors to develop alternatives – often costlier or less efficient – solutions. This provides the company with critical time to build market share and set technological standards. “Even at this early stage of our technology, we recognize that patents will determine how successfully we can roll out globally. Accordingly, we will further accelerate our patent strategy to control the standard, the platform – and ultimately the direction in which this market evolves. We are not just automating field catering – we are redefining how critical missions are sustained, supported, and supplied”, said Nikolas Bullwinkel, Founder and CEO of Circus SE. Following the successful grant of its core technology patent for the CA-1 AI robot in April 2025, these six additional filings mark Circus’ entry into a phase of comprehensive intellectual property protection. The company’s clear objective is to establish an unassailable technological lead in AI-driven robotics within the global defense market. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world’s first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply – on a mission to fuel humanity. Contact Circus SE
24.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Circus SE |
| St. Martin-Strasse 112 | |
| 81669 München | |
| Germany | |
| E-mail: | ir@circus-group.com |
| Internet: | https://www.circus-group.com/for-investors |
| ISIN: | DE000A2YN355 |
| WKN: | A2YN35 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
| EQS News ID: | 2218098 |
| End of News | EQS News Service |
|
|
2218098 24.10.2025 CET/CEST
Nachrichten zu Circus SE Inhaber-Akt
Analysen zu Circus SE Inhaber-Akt
Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall
Im BX Morning Call spricht die Schweizer Unternehmer-Ikone Etienne Jornod (OM Pharma) mit François Bloch und Olivia Hähnel (BX Swiss) über Führung, Wachstum, Kooperationen, seine Zeit bei der NZZ und darüber, warum Zuhören der wichtigste Leadership-Skill ist.
Die perfekte Folge für alle, die sich für Pharmastrategien, Galenica/Vifor und Unternehmertum interessieren.
🎯 Themen im Interview mit Etienne Jornod (OM Pharma)
– Antrieb und Führungsphilosophie eines Unternehmers
– Erfolgsweg von Galenica – Lehren aus Jahrzehnten Führung
– Frauenquote, Teamkultur und Leadership bei OM Pharma
– Internationale Expansion: China, USA und neue Märkte
– Forschung, Druck und Verantwortung in der Pharmaindustrie
– Inspiration, Balance und persönliche Haltung zum Erfolg
– Zukunftsvisionen: Schweiz, Unternehmertum und Investments
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach US-Zinsentscheid: US-Börsen schliessen uneins -- SMI und DAX letztlich schwächer -- Asiens Börsen schlussendlich im Plus - Nikkei mit AllzeithochDer heimische Aktienmarkt machte zur Wochenmitte Verluste. Der deutsche Aktienmarkt tendierte am Mittwoch abwärts. Die US-Börsen fanden keine gemeinsame Richtung. Die wichtigsten Aktienmärkte in Fernost verbuchten teilweise große Gewinne.


